These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.
|Articles|October 27, 2021
Cardiology Case Report: Weakness and Shortness of Breath
Author(s)Brady Pregerson, MD
The latest cardiology case report from Brady Pregerson, MD, features a man in his late 50’s presents to the hospital for generalized weakness and SOB. Check out the EKG and determine the correct diagnosis.
Advertisement
History: A man in his late 50’s presents to the hospital for generalized weakness and SOB. He denies syncope, palpitations, chest pain, fever, cough or other complaints.
Exam: Vitals are concerning for respirations in the 40’s, BP of 89/55 and a pulse in the 130’s.
An EKG is done:
What is the most likely cause of the EKG findings in this patient?
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
SubscribeAdvertisement
Related to this article
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
Advertisement
Advertisement